Acumen Pharmaceuticals 경영진
경영진 기준 점검 4/4
Acumen Pharmaceuticals CEO는 Dan O'Connell, Dec2014 에 임명되었습니다 의 임기는 11.75 년입니다. 총 연간 보상은 $1.86M, 34.7% 급여 및 65.3% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $868.82K 가치에 해당하는 회사 주식의 0.41% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 4.8 년과 5.8 년입니다.
핵심 정보
Dan O'Connell
최고경영자
US$1.9m
총 보수
| CEO 급여 비율 | 34.68% |
| CEO 재임 기간 | 11.8yrs |
| CEO 지분 보유율 | 0.4% |
| 경영진 평균 재임 기간 | 4.8yrs |
| 이사회 평균 재임 기간 | 5.8yrs |
최근 경영진 업데이트
Recent updates
새로운 내러티브 • Aug 14
Alzheimer’s Trial And Cash Burn Will Test Risky Oligomer Bet Yet Long-Term Upside Remains
Catalysts About Acumen Pharmaceuticals Acumen Pharmaceuticals is a clinical stage biopharmaceutical company focused on antibody therapies that selectively target amyloid beta oligomers in Alzheimer’s disease. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Jun 01
Oligomer Antibody And EBD Platform Will Reshape Early Alzheimer’s Treatment Over Time
Catalysts About Acumen Pharmaceuticals Acumen Pharmaceuticals is a clinical stage biotechnology company developing a beta oligomer targeted antibody therapies for Alzheimer's disease. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • May 17
Oligomer Antibody And Brain Delivery Advances Will Reshape Early Alzheimer Treatment Prospects
Catalysts About Acumen Pharmaceuticals Acumen Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing a beta oligomer targeted antibody therapies for Alzheimer’s disease. What are the underlying business or industry changes driving this perspective?분석 기사 • Aug 05
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jul 30
Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
Summary Acumen Pharmaceuticals develops treatments for Alzheimer's disease targeting toxic AβOs, with promising results for sabirnetug in phase 1 clinical trial Intercept-AD. The potential for early AD is approximately 7 million patients, positioning ABOS for significant market share if successful. Sabirnetug’s Phase 1 trial showed promising results, reducing brain amyloid plaques and supporting its mechanism of action for treating early Alzheimer's disease. Acumen Pharmaceuticals has a healthy cash runway, estimated at 3.5 years, and appears undervalued relative to its peers in the biotech sector. Despite the promising data, investing in ABOS is speculative due to the early stages of research and the potential long timeline to FDA approval. Read the full article on Seeking Alpha분석 기사 • Apr 21
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Sep 21
Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...분석 기사 • Feb 01
We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...분석 기사 • Oct 16
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Sep 28
Acumen Pharma at 11-month high on rivals’ Alzheimer’s data
The shares of microcap biotech Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) more than doubled in value on Wednesday after its rivals Biogen (BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESALY) announced promising late-stage data for experimental Alzheimer's therapy, lecanemab. In the trial involving nearly 1,800 patients, the amyloid targeting monoclonal antibody cut the cognitive and functional decline in the early stage of Alzheimer's by 27%, compared to placebo, the companies announced late Tuesday. With data validating the amyloid hypothesis in Alzheimer's, developers with similar drugs in their pipeline surged in value. Acumen (ABOS) is advancing its only drug candidate, ACU193 for Alzheimer's, with topline data from a Phase 1 trial expected in H1 2023. ACU193 is a humanized monoclonal antibody that selectively targets amyloid-beta oligomers, which, according to the company, are the most toxic and pathogenic form of amyloid-beta.Seeking Alpha • Jun 30
Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate
H.C. Wainwright has initiated Acumen Pharmaceuticals (NASDAQ:ABOS) with a buy rating saying the biopharma's early-stage Alzheimer's candidate, ACU193, has promise. The firm has a $15 price target (~207% return based on Wednesday's closing price). Unlike many other Alzheimer's therapies in development -- and marketed ones such as Biogen's (BIIB) Aduhelm (aducanumab) -- that target the removal of beta amyloid plaque from the brain, ACU193 works differently as a anti-amyloid-beta oligomer (AβO) monoclonal antibody. Analyst Andrew Fein noted that ACU193 "lacks the inflammatory effector functions of other [immunoglobulin] subclasses, thereby making it less prone to [amyloid-related imaging abnormalities], a major safety issue with current anti-[amyloid beta] therapies. Acumen (ABOS) said ACU193 prevents toxic AβOs from binding to dendritic spines and preserves neural function. The company added the candidate has the potential for disease slowing as well as cognitive improvement. The ongoing phase 1 trial is expected to enroll 62 subjects with mild cognitive impairment or mild dementia.분석 기사 • May 10
We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...분석 기사 • Jan 07
We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • Oct 01
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$105m |
| Mar 31 2026 | n/a | n/a | -US$113m |
| Dec 31 2025 | US$2m | US$646k | -US$121m |
| Sep 30 2025 | n/a | n/a | -US$133m |
| Jun 30 2025 | n/a | n/a | -US$137m |
| Mar 31 2025 | n/a | n/a | -US$116m |
| Dec 31 2024 | US$5m | US$621k | -US$102m |
| Sep 30 2024 | n/a | n/a | -US$82m |
| Jun 30 2024 | n/a | n/a | -US$65m |
| Mar 31 2024 | n/a | n/a | -US$56m |
| Dec 31 2023 | US$4m | US$598k | -US$52m |
| Sep 30 2023 | n/a | n/a | -US$49m |
| Jun 30 2023 | n/a | n/a | -US$46m |
| Mar 31 2023 | n/a | n/a | -US$45m |
| Dec 31 2022 | US$3m | US$570k | -US$43m |
| Sep 30 2022 | n/a | n/a | -US$38m |
| Jun 30 2022 | n/a | n/a | -US$32m |
| Mar 31 2022 | n/a | n/a | -US$83m |
| Dec 31 2021 | US$1m | US$525k | -US$101m |
| Sep 30 2021 | n/a | n/a | -US$93m |
| Jun 30 2021 | n/a | n/a | -US$92m |
| Mar 31 2021 | n/a | n/a | -US$32m |
| Dec 31 2020 | US$336k | US$240k | -US$7m |
보상 대 시장: Dan의 총 보수(USD1.86M)는 US 시장에서 비슷한 규모 기업의 평균(USD1.62M) 수준입니다.
보상과 수익: Dan의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Dan O'Connell (56 yo)
11.8yrs
재임 기간
US$1,863,567
보수
Mr. Daniel J. O’Connell, also known as Dan, MBA was a Key Advisor at Acidophil, LLC. He served as President until February 01, 2024 and serves as Chief Executive Officer of Acumen Pharmaceuticals, Inc. sin...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | 11.8yrs | US$1.86m | 0.41% $ 868.8k | |
| President & Chief Development Officer | 2.6yrs | US$1.01m | 0.017% $ 36.7k | |
| CFO & Chief Business Officer | 5.3yrs | US$948.79k | 0.17% $ 367.7k | |
| Co-Founder | 30.7yrs | US$42.00k | 데이터 없음 | |
| Co-Founder | no data | 데이터 없음 | 데이터 없음 | |
| Co-Founder | no data | 데이터 없음 | 데이터 없음 | |
| Chief Operating Officer | 5.7yrs | US$223.68k | 0.087% $ 183.8k | |
| Senior Vice President of Finance & Accounting and Corporate Controller | 3.2yrs | 데이터 없음 | 데이터 없음 | |
| VP & Head of Investor Relations | 4yrs | 데이터 없음 | 데이터 없음 | |
| Chief Legal Officer & Corporate Secretary | 4yrs | US$1.48m | 데이터 없음 | |
| Associate Director of Communications | 4.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief People Officer | 5.7yrs | 데이터 없음 | 데이터 없음 |
4.8yrs
평균 재임 기간
57yo
평균 나이
경험이 풍부한 관리: ABOS의 경영진은 경험이 있음으로 간주됩니다(평균 재임 4.8 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | 20.4yrs | US$1.86m | 0.41% $ 868.8k | |
| Member of Clinical & Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Clinical & Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 7.9yrs | US$107.05k | 0.44% $ 924.8k | |
| Independent Director | 4.4yrs | US$89.11k | 0.018% $ 37.4k | |
| Independent Director | 12.3yrs | US$79.11k | 0.018% $ 37.4k | |
| Member of Clinical & Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Clinical & Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Chairman of the Board | less than a year | US$82.74k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$84.61k | 0.018% $ 37.4k | |
| Member of Clinical & Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 5.3yrs | US$73.11k | 0.017% $ 36.9k |
5.8yrs
평균 재임 기간
63yo
평균 나이
경험이 풍부한 이사회: ABOS의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5.8 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/13 18:38 |
| 종가 | 2026/09/11 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Acumen Pharmaceuticals, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Jason Zemansky | BofA Global Research |
| Thomas Shrader | BTIG |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |